138 related articles for article (PubMed ID: 19445023)
21. FOLFIRINOX as first-line treatment for unresectable acinar cell carcinoma of the pancreas: a case report.
Schempf U; Sipos B; König C; Malek NP; Bitzer M; Plentz RR
Z Gastroenterol; 2014 Feb; 52(2):200-3. PubMed ID: 24526405
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
Lin CC; Hsu CH; Huang CY; Cheng AL; Vogelzang NJ; Pu YS
J Urol; 2007 Jan; 177(1):84-9; discussion 89. PubMed ID: 17162009
[TBL] [Abstract][Full Text] [Related]
23. [Pancreatic acinar cell carcinoma successfully treated with combination of oral TS-1 and intra-arterial cisplatin].
Kataoka Y; Nio Y; Yano S; Koike M; Hashimoto K; Itakura M; Itagaki T; Nishi T; Endo S; Higami T
Gan To Kagaku Ryoho; 2006 Apr; 33(4):525-8. PubMed ID: 16612167
[TBL] [Abstract][Full Text] [Related]
24. [Acinous-cell carcinoma of a metastatic pancreas treated by chemotherapy].
Corbinais S; Egreteau J; Garin L; Derrien G; Boucher E; Raoul JL
Gastroenterol Clin Biol; 2002 Dec; 26(12):1180-1. PubMed ID: 12520210
[No Abstract] [Full Text] [Related]
25. Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study.
Chang AY; Lopes G; Hsin KW; Lim R; Fong FK; Wong J
Clin Colorectal Cancer; 2007 Sep; 6(9):646-51. PubMed ID: 17945037
[TBL] [Abstract][Full Text] [Related]
26. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Yoo C; Hwang JY; Kim JE; Kim TW; Lee JS; Park DH; Lee SS; Seo DW; Lee SK; Kim MH; Han DJ; Kim SC; Lee JL
Br J Cancer; 2009 Nov; 101(10):1658-63. PubMed ID: 19826418
[TBL] [Abstract][Full Text] [Related]
27. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Trouilloud I; Dupont-Gossard AC; Malka D; Artru P; Gauthier M; Lecomte T; Aparicio T; Thirot-Bidault A; Lobry C; Asnacios A; Manet-Lacombe S; Fein F; Dubreuil O; Landi B; Zaanan A; Bonnetain F; Taïeb J
Eur J Cancer; 2014 Dec; 50(18):3116-24. PubMed ID: 25454414
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer.
Ch'ang HJ; Wang CC; Cheng AL; Hsu C; Lu YS; Chang MC; Lin JT; Wang HP; Shiah HS; Liu TW; Chang JY; Whang-Peng J; Chen LT
J Gastroenterol Hepatol; 2006 May; 21(5):874-9. PubMed ID: 16704539
[TBL] [Abstract][Full Text] [Related]
29. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
Olszewski AJ; Grossbard ML; Chung MS; Chalasani SB; Malamud S; Mirzoyev T; Kozuch PS
J Gastrointest Cancer; 2013 Jun; 44(2):182-9. PubMed ID: 23208490
[TBL] [Abstract][Full Text] [Related]
31. Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.
El-Hadaad HA; Wahba HA
J Gastrointest Cancer; 2013 Sep; 44(3):313-7. PubMed ID: 23606201
[TBL] [Abstract][Full Text] [Related]
32. Second-line treatment for pancreatic cancer.
Kaddis N; Saif MW
JOP; 2014 Jul; 15(4):344-7. PubMed ID: 25076339
[TBL] [Abstract][Full Text] [Related]
33. Systemic gemcitabine combined with hepatic arterial infusion chemotherapy with cisplatin, 5-fluorouracil, and isovorin for the treatment of advanced intrahepatic cholangiocarcinoma: a pilot study.
Marumoto M; Yamasaki T; Marumoto Y; Saeki I; Harima Y; Urata Y; Hidaka I; Ishikawa T; Takami T; Segawa M; Yamaguchi Y; Uchida K; Terai S; Sakaida I
Hepatogastroenterology; 2014; 61(129):162-7. PubMed ID: 24895814
[TBL] [Abstract][Full Text] [Related]
34. Gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) in patients with different gastroenteric malignancies.
Correale P; Cerretani D; Clerici M; Messinese S; Marsili S; Petrioli R; Cetta F; Savelli V; Guarnieri A; Pinto E; Giorgi G; Francini G
J Chemother; 2004 Apr; 16(2):206-10. PubMed ID: 15216958
[TBL] [Abstract][Full Text] [Related]
35. Effective intra-arterial chemotherapy for acinar cell carcinoma of the pancreas.
Ukei T; Okagawa K; Uemura Y; Miyauchi K; Kaneko T; Mizunoya S; Monden M
Dig Surg; 1999; 16(1):76-9. PubMed ID: 9949272
[TBL] [Abstract][Full Text] [Related]
36. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
[TBL] [Abstract][Full Text] [Related]
37. Complete remission of metastatic pancreatic cancer with cardiac involvement after gemcitabine, oxaliplatin and 46-h infusion of 5-fluorouracil/leucovorin.
Wu WC; Chen SC; Su YC; Chuang WL; Chen LT
J Gastroenterol Hepatol; 2004 Jun; 19(6):716-7. PubMed ID: 15151634
[No Abstract] [Full Text] [Related]
38. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.
Neuzillet C; Hentic O; Rousseau B; Rebours V; Bengrine-Lefèvre L; Bonnetain F; Lévy P; Raymond E; Ruszniewski P; Louvet C; Hammel P
World J Gastroenterol; 2012 Sep; 18(33):4533-41. PubMed ID: 22969226
[TBL] [Abstract][Full Text] [Related]
39. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
40. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
Schneitler S; Kröpil P; Riemer J; Antoch G; Knoefel WT; Häussinger D; Graf D
World J Gastroenterol; 2015 May; 21(20):6384-90. PubMed ID: 26034375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
